Kyverna Therapeutics (KYTX)

Executive Summary

Kyverna Therapeutics is a clinical-stage biotech pioneering CAR T-cell therapies for autoimmune diseases, aiming to replace chronic immunosuppression with potentially curative one-time treatments. Its lead candidate, KYV-101 (anti-CD19 CAR-T), is being evaluated across multiple indications including lupus nephritis (Phase 1/2), myasthenia gravis (Phase 2/3), multiple sclerosis (Phase 1), and others. The company went public on Nasdaq in early 2024 and has a market cap of ~$553M. Early clinical data have shown encouraging safety and efficacy signals, particularly in lupus nephritis where patients achieved drug-free remission. However, the stock has been volatile given the early stage and competitive landscape. With multiple readouts expected over the next 12-18 months, Kyverna represents a high-risk, high-reward opportunity in the emerging field of autoimmune cell therapy.

Upcoming Catalysts (preview)

• Q3 2026Lupus Nephritis Phase 1/2 data update (NCT05938725)70% success
• Q4 2026Myasthenia Gravis Phase 2/3 interim analysis (NCT06193889)60% success
• H2 2026Potential partnership or licensing deal for KYV-101 in a major autoimmune indication40% success